Table 1.
Included and Excluded trials in search of May 2023 281 studies
| publication number | excluded reason | included in review | class | RCT per study | unique intervention | study name | ref |
| 12 | 1 | CCP | 1 | 1 | CCP-CONV-ert | Alemany A, Millat-Martinez P, Corbacho-Monne M, et al. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respir Med 2022; 10(3): 278–88. | |
| 92 | 1 | CCP | 1 | CCP-COV-early | Gharbharan A, Jordans C, Zwaginga L, et al. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial. Clin Microbiol Infect 2022. | ||
| 132 | 1 | CCP | 1 | CCP-C3PO | Korley FK, Durkalski-Mauldin V, Yeatts SD, et al. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. N Engl J Med 2021; 385(21): 1951–60. | ||
| 150 | 1 | CCP | 1 | CCP-Argentina | Libster R, Perez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med 2021; 384(7): 610–8. | ||
| 252 | 1 | CCP | 1 | CCP-CSSC-004 | Sullivan DJ, Gebo KA, Shoham S, et al. Early Outpatient Treatment for Covid-19 with Convalescent Plasma. N Engl J Med 2022; 386(18): 1700–11. | ||
| 54 | 1 | mab | 1 | 1 | Bamlanivimab-BLAZE-1 | Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 2021; 384(3): 229–37. | |
| 72 | 1 | mab | 1 | 1 | Bebtelovimab-BLAZE-4 | Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv 2022: 2022.03.10.22272100. | |
| 73 | 1 | mab | 1 | 1 | Bamlanivimab/etesevimab-BLAZE-1 | Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med 2021; 385(15): 1382–92. | |
| 98 | 1 | mab | 1 | 1 | Sotrovimab-COMET-ICE | Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med 2021. | |
| 129 | 1 | mab | 1 | 1 | Regdanvimab-CT-P59–2 | Kim JY, Sandulescu O, Preotescu LL, et al. A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019. Open Forum Infect Dis 2022; 9(8): ofac406. | |
| 184 | 1 | mab | 1 | 1 | Tixagevimab–cilgavimab-TACKLE | Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2022; 10(10): 985–96. | |
| 195 | 1 | mab | 1 | 1 | Casirivimab/imdevimab-REGEN-COV Ph 1/2 | Norton T, Ali S, Sivapalasingam S, et al. REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 Results. medRxiv 2022: 2021.06.09.21257915. | |
| 251 | 1 | mab | 1 | Regdanvimab-CT-P59 | Streinu-Cercel A, Sandulescu O, Preotescu LL, et al. Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019. Open Forum Infect Dis 2022; 9(4): ofac053. | ||
| 275 | 1 | mab | 1 | Casirivimab/imdevimab-REGEN-COV Ph 3 | Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med 2021; 385(23): e81. | ||
| 7 | 1 | rp | 1 | 1 | Homeopathy-COVID-Simile | Adler UC, Adler MS, Padula AEM, et al. Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study). J Integr Med 2022; 20(3): 221–9. | |
| 24 | 1 | rp | 1 | Enoxaparin-OVID | Barco S, Voci D, Held U, et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Haematol 2022; 9(8): e585-e93. | ||
| 39 | 1 | rp | 3 | Metformin-COVID-OUT | Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med 2022; 387(7): 599–610. | ||
| 48 | 1 | rp | 1 | 1 | Niclosamide | Cairns DM, Dulko D, Griffiths JK, et al. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial. JAMA Netw Open 2022; 5(2): e2144942. | |
| 58 | 1 | rp | 1 | Inhaled Ciclesonide-COVIS | Clemency BM, Varughese R, Gonzalez-Rojas Y, et al. Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA Intern Med 2022; 182(1): 42–9. | ||
| 60 | 1 | rp | 3 | 1 | Aspirin-ACTIV-4B | Connors JM, Brooks MM, Sciurba FC, et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA 2021; 326(17): 1703–12. | |
| 61 | 1 | rp | 1 | 1 | Enoxaparin-ETHIC | Cools F, Virdone S, Sawhney J, et al. Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. Lancet Haematol 2022; 9(8): e594-e604. | |
| 76 | 1 | rp | 1 | 1 | Inhaled ciclesonide-COVERAGE | Duvignaud A, Lhomme E, Onaisi R, et al. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). Clin Microbiol Infect 2022; 28(7): 1010–6. | |
| 93 | 1 | rp | 1 | 1 | Sulodexide | Gonzalez-Ochoa AJ, Raffetto JD, Hernandez AG, et al. Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial. Thromb Haemost 2021; 121(7): 944–54. | |
| 107 | 1 | rp | 1 | Azithromycin-Atomic2 | Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med 2021; 9(10): 1130–40. | ||
| 115 | 1 | rp | 1 | Hydroxychloroquine-BMG | Johnston C, Brown ER, Stewart J, et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. EClinicalMedicine 2021; 33: 100773. | ||
| 128 | 1 | rp | 1 | 1 | Saliravira | Khorshiddoust RR, Khorshiddoust SR, Hosseinabadi T, et al. Efficacy of a multiple-indication antiviral herbal drug (Saliravira(R)) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study. Biomed Pharmacother 2022; 149: 112729. | |
| 145 | 1 | rp | 1 | 1 | Fluvoxamine-STOP COVID | Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA 2020; 324(22): 2292–300. | |
| 168 | 1 | rp | 1 | Fluvoxamine-ACTIV-6 | McCarthy MW, Naggie S, Boulware DR, et al. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA 2023; 329(4): 296–305. | ||
| 173 | 1 | rp | 1 | 1 | Resveratrol | McCreary MR, Schnell PM, Rhoda DA. Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19). Sci Rep 2022; 12(1): 10978. | |
| 281 | 1 | rp | 1 | Hydroxychloroquine-BCN PEP-CoV-2 | Mitja O, Corbacho-Monne M, Ubals M, et al. Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. Clin Infect Dis 2021; 73(11): e4073-e81. | ||
| 189 | 1 | rp | 1 | 1 | Ivermectin high dose-ACTIV-6 | Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA 2023; 329(11): 888–97. | |
| 187 | 1 | rp | 1 | Ivermectin-ACTIV-6 | Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA 2022; 328(16): 1595–603. | ||
| 198 | 1 | rp | 1 | 1 | Azithromycin-ACTION | Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA 2021; 326(6): 490–8. | |
| 214 | 1 | rp | 1 | 1 | Losartan-MN | Puskarich MA, Cummins NW, Ingraham NE, et al. A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine 2021; 37: 100957. | |
| 219 | 1 | rp | 1 | 1 | Metformin-TOGETHER | Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. Lancet Reg Health Am 2022; 6: 100142. | |
| 220 | 1 | rp | 1 | Fluvoxamine/budesonide-TOGETHER | Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, et al. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial. Ann Intern Med 2023; 176(5): 667–75. | ||
| 221 | 1 | rp | 1 | Fluvoxamine-TOGETHER | Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2022; 10(1): e42-e51. | ||
| 224 | 1 | rp | 1 | Ivermectin-TOGETHER | Reis G, Silva E, Silva DCM, et al. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med 2022; 386(18): 1721–31. | ||
| 227 | 1 | rp | 1 | Ivermectin Iran | Rezai MS, Ahangarkani F, Hill A, et al. Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials. Front Med (Lausanne) 2022; 9: 919708. | ||
| 229 | 1 | rp | 1 | Hydroxychloroquine/Azithromycin-Brazil | Rodrigues C, Freitas-Santos RS, Levi JE, et al. Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. Int J Antimicrob Agents 2021; 58(5): 106428. | ||
| 233 | 1 | rp | 1 | 1 | Nitazoxanide-Romark | Rossignol JF, Bardin MC, Fulgencio J, Mogelnicki D, Brechot C. A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19. EClinicalMedicine 2022; 45: 101310. | |
| 241 | 1 | rp | 1 | 1 | Hydroxychloroquine-AH COVID-19 | Schwartz I, Boesen ME, Cerchiaro G, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. CMAJ Open 2021; 9(2): E693-E702. | |
| 245 | 1 | rp | 1 | Hydroxychloroquine-COVID-19 PEP | Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. Ann Intern Med 2020; 173(8): 623–31. | ||
| 249 | 1 | rp | 1 | Hydroxychloroquine-Utah | Spivak AM, Barney BJ, Greene T, et al. A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. Microbiol Spectr 2023; 11(2): e0467422. | ||
| 257 | 1 | rp | 1 | 1 | Colchicine-COLCORONA | Tardif JC, Bouabdallaoui N, ĽAllier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med 2021; 9(8): 924–32. | |
| 259 | 1 | rp | 3 | 1 | Zinc | Thomas S, Patel D, Bittel B, et al. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial. JAMA Netw Open 2021; 4(2): e210369. | |
| 36 | 1 | sma | 1 | 1 | Favipiravir-Avi-Mild-19 | Bosaeed M, Alharbi A, Mahmoud E, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin Microbiol Infect 2022; 28(4): 602–8. | |
| 46 | 1 | sma | 1 | Molnupiravir-PANORAMIC | Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 2023; 401(10373): 281–93. | ||
| 82 | 1 | sma | 1 | 1 | Interferon Lambda-ILIAD | Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med 2021; 9(5): 498–510. | |
| 95 | 1 | sma | 1 | 1 | Remdesivir-PINETREE | Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med 2022; 386(4): 305–15. | |
| 100 | 1 | sma | 1 | 1 | Nirmatrelvir/ritonavir-EPIC-HR | Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022; 386(15): 1397–408. | |
| 112 | 1 | sma | 1 | Interferon Lambda-COVID-Lambda | Jagannathan P, Andrews JR, Bonilla H, et al. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nature Communications 2021; 12(1): 1967. | ||
| 113 | 1 | sma | 1 | Molnupiravir-MOVe-OUT | Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med 2022; 386(6): 509–20. | ||
| 118 | 1 | sma | 1 | Lopinavir/ritonavir-TREAT NOW | Kaizer AM, Shapiro NI, Wild J, et al. Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial. Int J Infect Dis 2023; 128: 223–9. | ||
| 159 | 1 | sma | 3 | Favipiravir/Lopinavir/Ritonavir-FLARE | Lowe DM, Brown LK, Chowdhury K, et al. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. PLoS Med 2022; 19(10): e1004120. | ||
| 203 | 1 | sma | 1 | 1 | Tenofovir/Emtricitabine-AR0-CORONA | Parienti JJ, Prazuck T, Peyro-Saint-Paul L, et al. Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial. EClinicalMedicine 2021; 38: 100993. | |
| 222 | 1 | sma | 2 | 1 | Lopinavir/ritonavir-TOGETHER | Reis G, Moreira Silva E, Medeiros Silva DC, et al. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial. JAMA Netw Open 2021; 4(4): e216468. | |
| 223 | 1 | sma | 1 | Interferon Lambda-TOGETHER | Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. N Engl J Med 2023; 388(6): 518–28. | ||
| 231 | 1 | sma | 1 | 1 | Sofosbuvir & daclatasvir-SOVODAK | Roozbeh F, Saeedi M, Alizadeh-Navaei R, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother 2021; 76(3): 753–7. | |
| 260 | 1 | sma | 1 | 1 | Molnupiravir-Aurobindo | Tippabhotla SK, Lahiri S, Rama Raju D, Kandi C, Prasad VN. Efficacy and Safety of Molnupiravir for the Treatment of Non-Hospitalized Adults With Mild COVID-19: A Randomized, Open-Label, Parallel-Group Phase 3 Trial. SSRN 2022; 4042673. | |
| 264 | 1 | sma | 1 | Favipiravir-Iran | Vaezi A, Salmasi M, Soltaninejad F, Salahi M, Javanmard SH, Amra B. Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. Adv Respir Med 2023; 91(1): 18–25. | ||
| 25 | guidelines | Bassetti M, Giacobbe DR, Bruzzi P, et al. Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infect Dis Ther 2021; 10(4): 1837–85. | |||||
| 62 | guidelines | Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Adv 2022; 6(2): 664–71. | |||||
| 80 | guidelines | Estcourt LJ, Cohn CS, Pagano MB, et al. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. Ann Intern Med 2022; 175(9): 1310–21. | |||||
| 139 | guidelines | Kyriakoulis KG, Dimakakos E, Kyriakoulis IG, et al. Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. J Clin Med 2022; 11(20). | |||||
| 6 | no hospitalizations | Adel Mehraban MS, Shirzad M, Mohammad Taghizadeh Kashani L, et al. Efficacy and safety of add-on Viola odorata L. in the treatment of COVID-19: A randomized double-blind controlled trial. J Ethnopharmacol 2023; 304: 116058. | |||||
| 15 | no hospitalizations | Alizadeh Z, Keyhanian N, Ghaderkhani S, Dashti-Khavidaki S, Shokouhi Shoormasti R, Pourpak Z. A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement. Iran J Allergy Asthma Immunol 2021; 20(4): 494–9. | |||||
| 29 | no hospitalizations | Bechlioulis A, Markozannes G, Chionidi I, et al. The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study. J Diabetes Complications 2023; 37(4): 108436. | |||||
| 31 | no hospitalizations | Ben Abdallah S, Mhalla Y, Trabelsi I, et al. Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial. Clin Infect Dis 2023; 76(2): 185–91. | |||||
| 32 | no hospitalizations | Bencheqroun H, Ahmed Y, Kocak M, et al. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2. Pathogens 2022; 11(5). | |||||
| 41 | no hospitalizations | Brennan CM, Nadella S, Zhao X, et al. Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial. Gut 2022; 71(5): 879–88. | |||||
| 44 | no hospitalizations | Bruno AM, Allshouse AA, Campbell HM, et al. Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 2022; 140(4): 575–83. | |||||
| 68 | no hospitalizations | De Boeck I, Cauwenberghs E, Spacova I, et al. Randomized, Double-Blind, Placebo-Controlled Trial of a Throat Spray with Selected Lactobacilli in COVID-19 Outpatients. Microbiol Spectr 2022; 10(5): e0168222. | |||||
| 103 | no hospitalizations | Hasanpour M, Safari H, Mohammadpour AH, et al. Efficacy of Covexir(R) (Ferula foetida oleo-gum) treatment in symptomatic improvement of patients with mild to moderate COVID-19: A randomized, double-blind, placebo-controlled trial. Phytother Res 2022; 36(12): 4504–15. | |||||
| 125 | no hospitalizations | Khan A, Iqtadar S, Mumtaz SU, et al. Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19-Results From a Pilot Open-Label, Randomized Controlled Trial. Front Pharmacol 2022; 13: 898062. | |||||
| 127 | no hospitalizations | Khoo SH, FitzGerald R, Saunders G, et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Infect Dis 2023; 23(2): 183–95. | |||||
| 133 | no hospitalizations | Kosmopoulos A, Bhatt DL, Meglis G, et al. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. iScience 2021; 24(9): 103040. | |||||
| 155 | no hospitalizations | Lofgren SM, Nicol MR, Bangdiwala AS, et al. Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. Open Forum Infect Dis 2020; 7(11): ofaa500. | |||||
| 230 | no hospitalizations | Rohani M, Mozaffar H, Mesri M, Shokri M, Delaney D, Karimy M. Evaluation and comparison of vitamin A supplementation with standard therapies in the treatment of patients with COVID-19. East Mediterr Health J 2022; 28(9): 673–81. | |||||
| 256 | no hospitalizations | Tandon M, Wu W, Moore K, et al. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial. Lancet Reg Health Southeast Asia 2022; 3: 100036. | |||||
| 1 | not outpt RCT | Aarnio-Peterson CM, Mara CA, Modi AC, Matthews A, Le Grange D, Shaffer A. Augmenting family based treatment with emotion coaching for adolescents with anorexia nervosa and atypical anorexia nervosa: Trial design and methodological report. Contemp Clin Trials Commun 2023; 33: 101118. | |||||
| 2 | not outpt RCT | Abbatecola AM, Incalzi RA, Malara A, et al. Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study. Vaccine 2022; 40(15): 2324–30. | |||||
| 3 | not outpt RCT | Abena PM, Decloedt EH, Bottieau E, et al. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. Am J Trop Med Hyg 2020; 102(6): 1184–8. | |||||
| 4 | not outpt RCT | Accelerating C-TI, Vaccines-6 Study G, Naggie S. Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. medRxiv 2022. | |||||
| 5 | not outpt RCT | Accelerating Covid-19 Therapeutic I, Vaccines-6 Study G, Naggie S. Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. medRxiv 2022. | |||||
| 9 | not outpt RCT | Agusti A, Guillen E, Ayora A, et al. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. Enferm Infecc Microbiol Clin (Engl Ed) 2022; 40(6): 289–95. | |||||
| 10 | not outpt RCT | Ainslie M, Brunette MF, Capozzoli M. Treatment Interruptions and Telemedicine Utilization in Serious Mental Illness: Retrospective Longitudinal Claims Analysis. JMIR Ment Health 2022; 9(3): e33092. | |||||
| 11 | not outpt RCT | Akca Sumengen A, Ocakci AF. Evaluation of the effect of an education program using cartoons and comics on disease management in children with asthma: a randomized controlled study. J Asthma 2023; 60(1): 11–23. | |||||
| 13 | not outpt RCT | Alemany A, Millat-Martinez P, Corbacho-Monne M, et al. Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial. EClinicalMedicine 2023; 57: 101898. | |||||
| 14 | not outpt RCT | Ali R, Patel A, Waqas MA, Trivedi K, Slim J. Functionality of Monoclonal Antibody Therapy in SARS-CoV-2. J Med Cases 2022; 13(8): 380–5. | |||||
| 16 | not outpt RCT | Aref ZF, Bazeed S, Hassan MH, et al. Possible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia. Infect Drug Resist 2022; 15: 5483–94. | |||||
| 17 | not outpt RCT | Avezum A, Oliveira GBF, Oliveira H, et al. Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial. Lancet Reg Health Am 2022; 11: 100243. | |||||
| 18 | not outpt RCT | Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun 2021; 12(1): 2349. | |||||
| 20 | not outpt RCT | Bahmer T, Borzikowsky C, Lieb W, et al. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multicentre, population-based cohort study. EClinicalMedicine 2022; 51: 101549. | |||||
| 21 | not outpt RCT | Baksh S, Heath SL, Fukuta Y, et al. Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID-19: a randomized trial. J Infect Dis 2023. | |||||
| 22 | not outpt RCT | Barati S, Feizabadi F, Khalaj H, et al. Evaluation of noscapine-licorice combination effects on cough relieving in COVID-19 outpatients: A randomized controlled trial. Front Pharmacol 2023; 14: 1102940. | |||||
| 23 | not outpt RCT | Barchuk A, Cherkashin M, Bulina A, et al. Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study. BMC Med 2022; 20(1): 312. | |||||
| 26 | not outpt RCT | Batalik L, Dosbaba F, Hartman M, Konecny V, Batalikova K, Spinar J. Long-term exercise effects after cardiac telerehabilitation in patients with coronary artery disease: 1-year follow-up results of the randomized study. Eur J Phys Rehabil Med 2021; 57(5): 807–14. | |||||
| 27 | not outpt RCT | Batioglu-Karaaltin A, Yigit O, Cakan D, et al. Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID-19. Clin Otolaryngol 2023. | |||||
| 28 | not outpt RCT | Bauer A, Schreinlechner M, Sappler N, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med 2021; 9(8): 863–72. | |||||
| 30 | not outpt RCT | Behrouzi B, Bhatt DL, Cannon CP, et al. Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. JAMA Netw Open 2022; 5(4): e228873. | |||||
| 33 | not outpt RCT | Bhatia T, Kumari N, Yadav A, et al. Feasibility, acceptability and evaluation of meditation to augment yoga practice among persons diagnosed with schizophrenia. Acta Neuropsychiatr 2022; 34(6): 330–43. | |||||
| 35 | not outpt RCT | Bledsoe J, Woller SC, Brooks M, et al. Clinically stable covid-19 patients presenting to acute unscheduled episodic care venues have increased risk of hospitalization: secondary analysis of a randomized control trial. BMC Infect Dis 2023; 23(1): 325. | |||||
| 37 | not outpt RCT | Boudreaux ED, Larkin C, Sefair AV, et al. Studying the implementation of Zero Suicide in a large health system: Challenges, adaptations, and lessons learned. Contemp Clin Trials Commun 2022; 30: 100999. | |||||
| 38 | not outpt RCT | Bramante CT, Buse J, Tamaritz L, et al. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. J Med Virol 2021; 93(7): 4273–9. | |||||
| 40 | not outpt RCT | Bramante CT, Johnson SG, Garcia V, et al. Diabetes medications and associations with Covid-19 outcomes in the N3C database: A national retrospective cohort study. PLoS One 2022; 17(11): e0271574. | |||||
| 47 | not outpt RCT | Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. New Microbes New Infect 2021; 43: 100915. | |||||
| 50 | not outpt RCT | Cavanna L, Citterio C. Randomised clinical trials on outpatient treatment of SARS-COV-2 infection: Light and shadows. Int J Clin Pract 2021; 75(12): e14896. | |||||
| 52 | not outpt RCT | Chawla A, Birger R, Wan H, et al. Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes. Clin Pharmacol Ther 2023; 113(6): 1337–45. | |||||
| 53 | not outpt RCT | Chen L, Zhou YZ, Zhou XM, et al. Evaluation of the "safe multidisciplinary app-assisted remote patient-self-testing (SMART) model" for warfarin home management during the COVID-19 pandemic: study protocol of a multi-center randomized controlled trial. BMC Health Serv Res 2021; 21(1): 875. | |||||
| 56 | not outpt RCT | Christie LJ, Fearn N, McCluskey A, et al. Remote constraint induced therapy of the upper extremity (ReCITE): A feasibility study protocol. Front Neurol 2022; 13: 1010449. | |||||
| 57 | not outpt RCT | Clark J, Tong SYC. In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery. Ann Intern Med 2023; 176(5): JC52. | |||||
| 59 | not outpt RCT | Cohen JB, Hanff TC, Corrales-Medina V, et al. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. J Clin Hypertens (Greenwich) 2020; 22(10): 1780–8. | |||||
| 63 | not outpt RCT | D'Ascanio L, Vitelli F, Cingolani C, Maranzano M, Brenner MJ, Di Stadio A. Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results. Eur Rev Med Pharmacol Sci 2021; 25(11): 4156–62. | |||||
| 64 | not outpt RCT | da Silva RM, Gebe Abreu Cabral P, de Souza SB, et al. Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. Front Med (Lausanne) 2023; 10: 1143485. | |||||
| 65 | not outpt RCT | Damery S, Jones J, O'Connell Francischetto E, Jolly K, Lilford R, Ferguson J. Remote Consultations Versus Standard Face-to-Face Appointments for Liver Transplant Patients in Routine Hospital Care: Feasibility Randomized Controlled Trial of myVideoClinic. J Med Internet Res 2021; 23(9): e19232. | |||||
| 66 | not outpt RCT | Davis JS, Ferreira D, Denholm JT, Tong SY. Clinical trials for the prevention and treatment of COVID-19: current state of play. Med J Aust 2020; 213(2): 86–93. | |||||
| 67 | not outpt RCT | Davoodi L, Abedi SM, Salehifar E, et al. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. Int J Clin Pract 2020; 74(11): e13600. | |||||
| 70 | not outpt RCT | Di Pierro F, Derosa G, Maffioli P, et al. Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. Int J Gen Med 2021; 14: 2359–66. | |||||
| 74 | not outpt RCT | Dube MP, Lemacon A, Barhdadi A, et al. Genetics of symptom remission in outpatients with COVID-19. Sci Rep 2021; 11(1): 10847. | |||||
| 75 | not outpt RCT | Dugani SB, Kiliaki SA, Nielsen ML, et al. Post-discharge early assessment with remote video link (PEARL) initiative for patients discharged from hospital medicine services. Hosp Pract (1995) 2022; 50(5): 379–86. | |||||
| 77 | not outpt RCT | Duvignaud A, Lhomme E, Pistone T, et al. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). Trials 2020; 21(1): 846. | |||||
| 78 | not outpt RCT | Eikelboom J, Rangarajan S, Jolly SS, et al. The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. CJC Open 2022; 4(6): 568–76. | |||||
| 81 | not outpt RCT | Fan Y, Shi Y, Zhang J, et al. The effects of narrative exposure therapy on COVID-19 patients with post-traumatic stress symptoms: A randomized controlled trial. J Affect Disord 2021; 293: 141–7. | |||||
| 84 | not outpt RCT | Fink T, Chen Q, Chong L, Hii MW, Knowles B. Telemedicine versus face-to-face follow up in general surgery: a randomized controlled trial. ANZ J Surg 2022; 92(10): 2544–50. | |||||
| 85 | not outpt RCT | Focosi D, Franchini M, Pirofski LA, et al. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev 2022; 35(3): e0020021. | |||||
| 88 | not outpt RCT | Geiger I, Kammerlander C, Hofer C, et al. Implementation of an integrated care programme to avoid fragility fractures of the hip in older adults in 18 Bavarian hospitals - study protocol for the cluster-randomised controlled fracture liaison service FLS-CARE. BMC Geriatr 2021; 21(1): 43. | |||||
| 89 | not outpt RCT | Geriak M, Haddad F, Kullar R, et al. Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia. Infect Dis Ther 2021; 10(3): 1323–30. | |||||
| 90 | not outpt RCT | Gerlier C, Pilmis B, Ganansia O, Le Monnier A, Nguyen Van JC. Clinical and operational impact of rapid point-of-care SARS-CoV-2 detection in an emergency department. Am J Emerg Med 2021; 50: 713–8. | |||||
| 91 | not outpt RCT | Ghany R, Palacio A, Dawkins E, et al. Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA. Diabetes Metab Syndr 2021; 15(2): 513–8. | |||||
| 96 | not outpt RCT | Group A-TL-CS, Lundgren JD, Grund B, et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N Engl J Med 2021; 384(10): 905–14. | |||||
| 97 | not outpt RCT | Grundeis F, Ansems K, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev 2023; 1(1): CD014962. | |||||
| 99 | not outpt RCT | Gupta A, Madhavan MV, Poterucha TJ, et al. Association Between Antecedent Statin Use and Decreased Mortality in Hospitalized Patients with COVID-19. Res Sq 2020. | |||||
| 101 | not outpt RCT | Hanna CR, Blyth KG, Burley G, et al. Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials 2020; 21(1): 935. | |||||
| 102 | not outpt RCT | Haran JP, Pinero JC, Zheng Y, Palma NA, Wingertzahn M. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Trials 2021; 22(1): 245. | |||||
| 104 | not outpt RCT | Hautmann C, Rausch J, Geldermann N, et al. Progress feedback in children and adolescents with internalizing and externalizing symptoms in routine care (OPTIE study): study protocol of a randomized parallel-group trial. BMC Psychiatry 2021; 21(1): 505. | |||||
| 105 | not outpt RCT | Hazan S, Dave S, Gunaratne AW, et al. Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients. Future Microbiol 2022; 17: 339–50. | |||||
| 106 | not outpt RCT | Helsingen LM, Loberg M, Refsum E, et al. Covid-19 transmission in fitness centers in Norway - a randomized trial. BMC Public Health 2021; 21(1): 2103. | |||||
| 108 | not outpt RCT | Hosseini FS, Malektojari A, Ghazizadeh S, et al. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials 2021; 22(1): 4. | |||||
| 109 | not outpt RCT | Hozayen SM, Zychowski D, Benson S, et al. Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. EClinicalMedicine 2021; 41: 101139. | |||||
| 111 | not outpt RCT | Indraratna P, Biswas U, Yu J, et al. Trials and Tribulations: mHealth Clinical Trials in the COVID-19 Pandemic. Yearb Med Inform 2021; 30(1): 272–9. | |||||
| 114 | not outpt RCT | Jering KS, Claggett BL, Pfeffer MA, et al. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. Circ Heart Fail 2023; 16(5): e010259. | |||||
| 116 | not outpt RCT | Kadali RAK, Janagama R, Peruru S, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol 2021; 93(7): 4420–9. | |||||
| 117 | not outpt RCT | Kaduszkiewicz H, Kochen MM, Kluge S, et al. Recommendations for the Outpatient Drug Treatment of Patients With COVID-19. Dtsch Arztebl Int 2022; 119(19): 342–9. | |||||
| 119 | not outpt RCT | Kaizer AM, Wild J, Lindsell CJ, et al. Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial. Trials 2022; 23(1): 273. | |||||
| 120 | not outpt RCT | Kapepula PM, Kabengele JK, Kingombe M, et al. Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials. Am J Trop Med Hyg 2020; 103(3): 960–4. | |||||
| 121 | not outpt RCT | Karaba AH, Johnston TS, Beck E, et al. Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment. mBio 2023; 14(1): e0328722. | |||||
| 123 | not outpt RCT | Keitel V, Jensen B, Feldt T, et al. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial. Trials 2021; 22(1): 343. | |||||
| 124 | not outpt RCT | Khair A, Cromwell PM, Abdelatif A, et al. Text Messaging, Telephone, or In-Person Outpatient Visit to the Surgical Clinic: A Randomized Trial. J Surg Res 2022; 280: 226–33. | |||||
| 126 | not outpt RCT | Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother 2021; 76(12): 3286–95. | |||||
| 130 | not outpt RCT | Kip KE, McCreary EK, Collins K, et al. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study. Ann Intern Med 2023; 176(4): 496–504. | |||||
| 134 | not outpt RCT | Kramer A, Prinz C, Fichtner F, et al. Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev 2022; 6(6): CD015209. | |||||
| 135 | not outpt RCT | Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2022; 22(3): 329–40. | |||||
| 136 | not outpt RCT | Krzyzanowska MK, Julian JA, Gu CS, et al. Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial. BMJ 2021; 375: e066588. | |||||
| 138 | not outpt RCT | Kupferschmitt A, Hinterberger T, Montanari I, et al. Relevance of the post-COVID syndrome within rehabilitation (PoCoRe): study protocol of a multicentre study with different specialisations. BMC Psychol 2022; 10(1): 189. | |||||
| 140 | not outpt RCT | Lee MT, George J, Shahab H, Hermel M, Rana JS, Virani SS. Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions. Curr Atheroscler Rep 2022; 24(1): 61–72. | |||||
| 141 | not outpt RCT | Lee TC, Bortolussi-Courval E, Belga S, et al. Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis. Eur Respir J 2022; 59(5). | |||||
| 142 | not outpt RCT | Lee TC, Morris AM, Grover SA, Murthy S, McDonald EG. Outpatient Therapies for COVID-19: How Do We Choose? Open Forum Infect Dis 2022; 9(3): ofac008. | |||||
| 144 | not outpt RCT | Legacy M, Seely D, Conte E, et al. Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial. BMJ Open 2022; 12(3): e057024. | |||||
| 146 | not outpt RCT | Les Bujanda I, Loureiro-Amigo J, Bastons FC, et al. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial. Trials 2021; 22(1): 43. | |||||
| 148 | not outpt RCT | Levine AC, Fukuta Y, Huaman MA, et al. COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized Trials. Clin Infect Dis 2023. | |||||
| 149 | not outpt RCT | Li W, Xie L, Zhu X, et al. Effectiveness and safety of Qingfei Dayuan granules for treating influenza and upper respiratory tract infections manifested by the pulmonary heat-toxin syndrome: A multicenter, randomized, double-blind, placebo-controlled trial. Front Pharmacol 2023; 14: 1133560. | |||||
| 151 | not outpt RCT | Licchetta L, Trivisano M, Baldin E, et al. TELEmedicine for EPIlepsy Care (TELE-EPIC): protocol of a randomised, open controlled non-inferiority clinical trial. BMJ Open 2021; 11(12): e053980. | |||||
| 153 | not outpt RCT | Liu HH, Ezekowitz MD, Columbo M, et al. The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic. Trials 2021; 22(1): 603. | |||||
| 156 | not outpt RCT | Lokhandwala T, Acharya M, Farrelly E, Coutinho AD, Bell CF, Svedsater H. Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression. J Manag Care Spec Pharm 2022; 28(11): 1261–71. | |||||
| 160 | not outpt RCT | Lui G, Guaraldi G. Drug treatment of COVID-19 infection. Curr Opin Pulm Med 2023; 29(3): 174–83. | |||||
| 162 | not outpt RCT | Manenti L, Maggiore U, Fiaccadori E, et al. Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study. PLoS One 2021; 16(3): e0248276. | |||||
| 163 | not outpt RCT | Mao Z, Li X, Dacosta-Urbieta A, et al. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe. Vaccine 2023; 41(16): 2707–15. | |||||
| 165 | not outpt RCT | Mason JS, Crowell MS, Brindle RA, et al. The Effect of Blood Flow Restriction Training on Muscle Atrophy Following Meniscal Repair or Chondral Restoration Surgery in Active Duty Military: A Randomized Controlled Trial. J Sport Rehabil 2022; 31(1): 77–84. | |||||
| 166 | not outpt RCT | Mazzaferri F, Mirandola M, Savoldi A, et al. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. Elife 2022; 11. | |||||
| 170 | not outpt RCT | McCreary EK, Bariola JR, Minnier T, et al. Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days. Contemp Clin Trials 2022; 113: 106652. | |||||
| 174 | not outpt RCT | McCullough PA, Kelly RJ, Ruocco G, et al. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med 2021; 134(1): 16–22. | |||||
| 175 | not outpt RCT | McKinnon JE, Wang DD, Zervos M, et al. Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study. Int J Infect Dis 2022; 116: 167–73. | |||||
| 176 | not outpt RCT | Mesri M, Esmaeili Saber SS, Godazi M, et al. The effects of combination of Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial. J Complement Integr Med 2021; 18(4): 775–81. | |||||
| 179 | not outpt RCT | Miguel-Cruz A, Ladurner AM, Kohls-Wiebe M, Rawani D. The Effects of 3D Immersion Technology (3Scape) on Mental Health in Outpatients From a Short-Term Assessment, Rehabilitation, and Treatment Program: Feasibility Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2021; 10(9): e25017. | |||||
| 178 | not outpt RCT | Miguel-Cruz A, Sr., Guptill C, Gregson G, et al. Determining the Effectiveness of a New Device for Hand Therapy (The FEPSim Device): Feasibility Protocol for a Randomized Controlled Trial Study. JMIR Res Protoc 2021; 10(5): e22145. | |||||
| 181 | not outpt RCT | Mills FP, Reis G, Wilson LA, et al. Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model. Am J Trop Med Hyg 2023; 108(1): 101–6. | |||||
| 182 | not outpt RCT | Miryan M, Bagherniya M, Sahebkar A, et al. Effects of curcumin-piperine co-supplementation on clinical signs, duration, severity, and inflammatory factors in patients with COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials 2020; 21(1): 1027. | |||||
| 183 | not outpt RCT | Levine AC, Fukuta Y, Huaman MA, et al. COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized Trials. Clin Infect Dis 2023. | |||||
| 185 | not outpt RCT | Levine AC, Fukuta Y, Huaman MA, et al. COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized Trials. medRxiv 2022. | |||||
| 186 | not outpt RCT | Li W, Xie L, Zhu X, et al. Effectiveness and safety of Qingfei Dayuan granules for treating influenza and upper respiratory tract infections manifested by the pulmonary heat-toxin syndrome: A multicenter, randomized, double-blind, placebo-controlled trial. Front Pharmacol 2023; 14: 1133560. | |||||
| 190 | not outpt RCT | Licchetta L, Trivisano M, Baldin E, et al. TELEmedicine for EPIlepsy Care (TELE-EPIC): protocol of a randomised, open controlled non-inferiority clinical trial. BMJ Open 2021; 11(12): e053980. | |||||
| 191 | not outpt RCT | Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials. J Med Virol 2022; 94(5): 2222–9. | |||||
| 193 | not outpt RCT | Liu HH, Ezekowitz MD, Columbo M, et al. The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic. Trials 2021; 22(1): 603. | |||||
| 196 | not outpt RCT | Lofgren SM, Nicol MR, Bangdiwala AS, et al. Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19. medRxiv 2020. | |||||
| 197 | not outpt RCT | Lofgren SM, Nicol MR, Bangdiwala AS, et al. Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. Open Forum Infect Dis 2020; 7(11): ofaa500. | |||||
| 200 | not outpt RCT | Lokhandwala T, Acharya M, Farrelly E, Coutinho AD, Bell CF, Svedsater H. Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression. J Manag Care Spec Pharm 2022; 28(11): 1261–71. | |||||
| 201 | not outpt RCT | Lopes RD, de Barros ESPGM, Furtado RHM, et al. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial. Am Heart J 2021; 238: 1–11. | |||||
| 202 | not outpt RCT | Lother SA, Abassi M, Agostinis A, et al. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Can J Anaesth 2020; 67(9): 1201–11. | |||||
| 204 | not outpt RCT | Lui G, Guaraldi G. Drug treatment of COVID-19 infection. Curr Opin Pulm Med 2023; 29(3): 174–83. | |||||
| 206 | not outpt RCT | Malin JJ, Weibel S, Gruell H, Kreuzberger N, Stegemann M, Skoetz N. Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis. J Antimicrob Chemother 2023. | |||||
| 208 | not outpt RCT | Manenti L, Maggiore U, Fiaccadori E, et al. Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study. PLoS One 2021; 16(3): e0248276. | |||||
| 209 | not outpt RCT | Mao Z, Li X, Dacosta-Urbieta A, et al. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe. Vaccine 2023; 41(16): 2707–15. | |||||
| 210 | not outpt RCT | Martins-Filho PR, Ferreira LC, Heimfarth L, Araujo AAS, Quintans-Junior LJ. Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. Lancet Reg Health Am 2021; 2: 100062. | |||||
| 211 | not outpt RCT | Mason JS, Crowell MS, Brindle RA, et al. The Effect of Blood Flow Restriction Training on Muscle Atrophy Following Meniscal Repair or Chondral Restoration Surgery in Active Duty Military: A Randomized Controlled Trial. J Sport Rehabil 2022; 31(1): 77–84. | |||||
| 212 | not outpt RCT | Mazzaferri F, Mirandola M, Savoldi A, et al. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. Elife 2022; 11. | |||||
| 213 | not outpt RCT | McCarthy MW, Naggie S, Boulware DR, et al. Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. medRxiv 2022. | |||||
| 215 | not outpt RCT | McCoy J, Goren A, Cadegiani FA, et al. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front Med (Lausanne) 2021; 8: 668698. | |||||
| 218 | not outpt RCT | McCreary EK, Bariola JR, Minnier T, et al. Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days. Contemp Clin Trials 2022; 113: 106652. | |||||
| 225 | not outpt RCT | McCreary EK, Bariola JR, Wadas RJ, et al. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19. JAMA Netw Open 2022; 5(4): e226920. | |||||
| 228 | not outpt RCT | McCreary MR, Schnell PM, Rhoda DA. Randomized Double-blind Placebo-controlled Proof-of-concept Trial of Resveratrol for Outpatient Treatment of Mild Coronavirus Disease (COVID-19). Res Sq 2021. | |||||
| 232 | not outpt RCT | McCullough PA, Kelly RJ, Ruocco G, et al. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med 2021; 134(1): 16–22. | |||||
| 234 | not outpt RCT | McKinnon JE, Wang DD, Zervos M, et al. Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study. Int J Infect Dis 2022; 116: 167–73. | |||||
| 235 | not outpt RCT | Mesri M, Esmaeili Saber SS, Godazi M, et al. The effects of combination of Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial. J Complement Integr Med 2021; 18(4): 775–81. | |||||
| 237 | not outpt RCT | Migliorini F, Vaishya R, Eschweiler J, Oliva F, Hildebrand F, Maffulli N. Vitamins C and D and COVID-19 Susceptibility, Severity and Progression: An Evidence Based Systematic Review. Medicina (Kaunas) 2022; 58(7). | |||||
| 238 | not outpt RCT | Miguel-Cruz A, Ladurner AM, Kohls-Wiebe M, Rawani D. The Effects of 3D Immersion Technology (3Scape) on Mental Health in Outpatients From a Short-Term Assessment, Rehabilitation, and Treatment Program: Feasibility Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2021; 10(9): e25017. | |||||
| 240 | not outpt RCT | Miguel-Cruz A, Sr., Guptill C, Gregson G, et al. Determining the Effectiveness of a New Device for Hand Therapy (The FEPSim Device): Feasibility Protocol for a Randomized Controlled Trial Study. JMIR Res Protoc 2021; 10(5): e22145. | |||||
| 242 | not outpt RCT | Millat-Martinez P, Gharbharan A, Alemany A, et al. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nat Commun 2022; 13(1): 2583. | |||||
| 243 | not outpt RCT | Mills FP, Reis G, Wilson LA, et al. Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model. Am J Trop Med Hyg 2023; 108(1): 101–6. | |||||
| 244 | not outpt RCT | Miryan M, Bagherniya M, Sahebkar A, et al. Effects of curcumin-piperine co-supplementation on clinical signs, duration, severity, and inflammatory factors in patients with COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials 2020; 21(1): 1027. | |||||
| 246 | not outpt RCT | Mitja O, Reis G, Boulware DR, et al. Hydroxychloroquine for treatment of non-hospitalized adults with COVID-19: A meta-analysis of individual participant data of randomized trials. Clin Transl Sci 2023; 16(3): 524–35. | |||||
| 247 | not outpt RCT | Muschol J, Heinrich M, Heiss C, et al. Economic and Environmental Impact of Digital Health App Video Consultations in Follow-up Care for Patients in Orthopedic and Trauma Surgery in Germany: Randomized Controlled Trial. J Med Internet Res 2022; 24(11): e42839. | |||||
| 250 | not outpt RCT | Nachega JB, Leisegang R, Kallay O, Mills EJ, Zumla A, Lester RT. Mobile Health Technology for Enhancing the COVID-19 Response in Africa: A Potential Game Changer? Am J Trop Med Hyg 2020; 103(1): 3–5. | |||||
| 253 | not outpt RCT | Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin 600 mug/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial. medRxiv 2022. | |||||
| 258 | not outpt RCT | Nappi F, Iervolino A, Avtaar Singh SS. Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. Biomedicines 2022; 10(2). | |||||
| 262 | not outpt RCT | Narayanan D, Parimon T. Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus. Int J Mol Sci 2022; 23(14). | |||||
| 263 | not outpt RCT | Nascimento L, Mendes LA, Torres-Castro R, et al. Physical performance testing in post-COVID-19 patients: protocol for a systematic review of psychometric measurement properties. BMJ Open 2023; 13(4): e067392. | |||||
| 265 | not outpt RCT | Ngo BT, Marik P, Kory P, et al. The time to offer treatments for COVID-19. Expert Opin Investig Drugs 2021; 30(5): 505–18. | |||||
| 267 | not outpt RCT | Nicastri E, Marinangeli F, Pivetta E, et al. A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19. EClinicalMedicine 2022; 48: 101450. | |||||
| 268 | not outpt RCT | Nyirenda JL, Sofroniou M, Toews I, et al. Fluvoxamine for the treatment of COVID-19. Cochrane Database Syst Rev 2022; 9(9): CD015391. | |||||
| 269 | not outpt RCT | Ogletree ML, Chander Chiang K, Kulshrestha R, Agarwal A, Agarwal A, Gupta A. Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A(2) and Prostaglandin D(2) Receptor Antagonist: A Four-Patient Case Series Report. Front Pharmacol 2022; 13: 904020. | |||||
| 271 | not outpt RCT | Oliveira GBF, Neves P, Oliveira HA, et al. Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE - Coalition COVID-19 Brazil VIII). Arq Bras Cardiol 2023; 120(3): e20220431. | |||||
| 272 | not outpt RCT | Oliveira Junior HA, Ferri CP, Boszczowski I, et al. Rationale and Design of the COVID-19 Outpatient Prevention Evaluation (COPE - Coalition V) Randomized Clinical Trial: Hydroxychloroquine vs. Placebo in Non-Hospitalized Patients. Arq Bras Cardiol 2022; 118(2): 378–87. | |||||
| 273 | not outpt RCT | Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years - United States, June-September 2021. MMWR Morb Mortal Wkly Rep 2021; 70(42): 1483–8. | |||||
| 276 | not outpt RCT | Pan DZ, Odorizzi PM, Schoenichen A, et al. Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting. Commun Med (Lond) 2023; 3(1): 2. | |||||
| 278 | not outpt RCT | Pembroke S, Rogerson S, Coyne I. Conducting a randomised controlled trial of a psychosocial intervention for adolescents with type 1 diabetes during COVID-19: recommendations to overcome the challenges complicated by inconsistent public health guidelines on research. Trials 2022; 23(1): 362. | |||||
| 279 | not outpt RCT | Pham B, Rios P, Radhakrishnan A, et al. Comparative-effectiveness research of COVID-19 treatment: a rapid scoping review. BMJ Open 2022; 12(6): e045115. | |||||
| 280 | not outpt RCT | Pinzon MA, Ortiz S, Holguin H, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS One 2021; 16(5): e0252057. | |||||
| 51 | open label | Plasse TF, Delgado B, Potts J, et al. A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19. Int J Infect Dis 2023; 128: 148–56. | |||||
| 79 | open label | Popp M, Reis S, Schiesser S, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev 2022; 6(6): CD015017. | |||||
| 157 | open label | Popp M, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev 2021; 7(7): CD015017. | |||||
| 248 | open label | Popp M, Stegemann M, Riemer M, et al. Antibiotics for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 10(10): CD015025. | |||||
| 254 | open label | Portal-Celhay C, Forleo-Neto E, Eagan W, et al. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial. JAMA Netw Open 2022; 5(8): e2225411. | |||||
| 110 | propensity matcch | Powell-Jackson T, King JJC, Makungu C, et al. Infection prevention and control compliance in Tanzanian outpatient facilities: a cross-sectional study with implications for the control of COVID-19. Lancet Glob Health 2020; 8(6): e780-e9. | |||||
| 171 | propensity matcch | Procter BC, Ross C, Pickard V, Smith E, Hanson C, McCullough PA. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Rev Cardiovasc Med 2020; 21(4): 611–4. | |||||
| 42 | protocol | Puspitasari AJ, Heredia D, Coombes BJ, et al. Feasibility and Initial Outcomes of a Group-Based Teletherapy Psychiatric Day Program for Adults With Serious Mental Illness: Open, Nonrandomized Trial in the Context of COVID-19. JMIR Ment Health 2021; 8(3): e25542. | |||||
| 49 | protocol | Rahman AE, Hossain AT, Nair H, et al. Prevalence of hypoxaemia in children with pneumonia in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Glob Health 2022; 10(3): e348-e59. | |||||
| 94 | protocol | Rahmati M, Molanouri Shamsi M, Woo W, et al. Effects of physical rehabilitation interventions in COVID-19 patients following discharge from hospital: A systematic review. J Integr Med 2023; 21(2): 149–58. | |||||
| 158 | protocol | Rajkumar T, Freyne J, Varnfield M, et al. Remote blood pressure monitoring in high risk pregnancy - study protocol for a randomised controlled trial (REMOTE CONTROL trial). Trials 2023; 24(1): 334. | |||||
| 199 | protocol | Reis S, Metzendorf MI, Kuehn R, et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst Rev 2022; 9(9): CD015395. | |||||
| 236 | protocol | Reis S, Popp M, Schiesser S, et al. Anticoagulation in COVID-19 patients - An updated systematic review and meta-analysis. Thromb Res 2022; 219: 40–8. | |||||
| 169 | retracted | Rizk JG, Gupta A, Lazo JG, Jr., et al. To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Semin Thromb Hemost 2023; 49(1): 62–72. | |||||
| 19 | review | Rohani M, Mozaffar H, Mesri M, Shokri M, Delaney D, Karimy M. Evaluation and comparison of vitamin A supplementation with standard therapies in the treatment of patients with COVID-19. East Mediterr Health J 2022; 28(9): 673–81. | |||||
| 34 | review | Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. JAMA Netw Open 2020; 3(12): e2029058. | |||||
| 45 | review | Rubin DJ, Shah AA. Predicting and Preventing Acute Care Re-Utilization by Patients with Diabetes. Curr Diab Rep 2021; 21(9): 34. | |||||
| 55 | review | Ruzhentsova TA, Oseshnyuk RA, Soluyanova TN, et al. Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19. Am J Transl Res 2021; 13(11): 12575–87. | |||||
| 69 | review | Saiz-Rodriguez M, Pena T, Lazaro L, et al. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial. Trials 2020; 21(1): 632. | |||||
| 71 | review | Salovaara PK, Li C, Nicholson A, Lipsitz SR, Natarajan S. Navigating COVID-19 and related challenges to completing clinical trials: Lessons from the PATRIOT and STEP-UP randomized prevention trials. Clin Trials 2023; 20(2): 153–65. | |||||
| 83 | review | Sanchez-Rico M, Limosin F, Vernet R, et al. Hydroxyzine Use and Mortality in Patients Hospitalized for COVID-19: A Multicenter Observational Study. J Clin Med 2021; 10(24). | |||||
| 86 | review | Sanghavi D, Bansal P, Kaur IP, et al. Impact of colchicine on mortality and morbidity in COVID-19: a systematic review. Ann Med 2022; 54(1): 775–89. | |||||
| 87 | review | Savoldi A, Morra M, De Nardo P, et al. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study. Eur J Clin Microbiol Infect Dis 2022; 41(7): 1065–76. | |||||
| 122 | review | Schwartz RA, Suskind RM. Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. Dermatol Ther 2020; 33(4): e13785. | |||||
| 131 | review | Shim MS, Kim S, Choi M, Choi JY, Park CG, Kim GS. Developing an app-based self-management program for people living with HIV: a randomized controlled pilot study during the COVID-19 pandemic. Sci Rep 2022; 12(1): 19401. | |||||
| 137 | review | Siami Z, Aghajanian S, Mansouri S, et al. Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial. Int J Infect Dis 2021; 108: 306–8. | |||||
| 143 | review | Skovsgaard CV, Kruse M, Hjollund N, Maribo T, de Thurah A. Cost-effectiveness of a telehealth intervention in rheumatoid arthritis: economic evaluation of the Telehealth in RA (TeRA) randomized controlled trial. Scand J Rheumatol 2023; 52(2): 118–28. | |||||
| 152 | review | So H, Chow E, Cheng IT, et al. Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: The 6-month results of a randomized controlled trial. Lupus 2022; 31(4): 488–94. | |||||
| 161 | review | Song JY, Yoon JG, Seo YB, et al. Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial. J Clin Med 2021; 10(16). | |||||
| 164 | review | Spyropoulos AC, Connors JM, Douketis JD, et al. Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. J Thromb Haemost 2022; 20(10): 2226–36. | |||||
| 177 | review | Tafler L, Danilevsky A, Seth D. Azithromycin in the Successful Management of COVID-19: A Family Physician's Perspective. Cureus 2021; 13(4): e14574. | |||||
| 192 | review | Takayama S, Namiki T, Ito T, et al. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial. Trials 2020; 21(1): 827. | |||||
| 205 | review | Talasaz AH, Sadeghipour P, Kakavand H, et al. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol 2021; 77(15): 1903–21. | |||||
| 216 | review | Tandon M, Wu W, Moore K, et al. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial. Lancet Reg Health Southeast Asia 2022; 3: 100036. | |||||
| 217 | review | Thomas JJ, Becker KR, Breithaupt L, et al. Cognitive-behavioral therapy for adults with avoidant/restrictive food intake disorder. J Behav Cogn Ther 2021; 31(1): 47–55. | |||||
| 226 | review | Tunjungputri RN, Tetrasiwi EN, Mulansari NA, Harimurti K, Nelwan EJ. Parenteral and Oral Anticoagulant Treatment for Hospitalized and Post-Discharge COVID-19 Patients: A Systematic Review and Meta-Analysis. Acta Med Indones 2022; 54(2): 190–209. | |||||
| 239 | review | Turan B, Akinci MA. Changing Trends of Diagnoses in a Child and Adolescent Psychiatry Outpatient Clinic Before and During COVID-19: An Analysis of Registered Data. Psychiatr Danub 2023; 35(1): 92–6. | |||||
| 255 | review | Turkia M. The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19. Cureus 2020; 12(12): e12403. | |||||
| 261 | review | Vainio PJ, Hietasalo P, Koivisto AL, et al. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial. Trials 2021; 22(1): 44. | |||||
| 266 | review | Vatvani AD, Kurniawan A, Hariyanto TI. Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials. Ann Pharmacother 2023: 10600280231162243. | |||||
| 277 | review | Venkatesh N, Paldus B, Lee MH, MacIsaac RJ, Jenkins AJ, O'Neal DN. COVID-19, Type 1 Diabetes Clinical Practice, Research, and Remote Medical Care: A View From the Land Down-Under. J Diabetes Sci Technol 2020; 14(4): 803–4. | |||||
| 43 | sub study | Verma N, Buch B, Taralekar R, Acharya S. Diagnostic concordance of telemedicine as compared to face-to-face care in primary health care clinics in rural India: a randomized crossover trial. JMIR Form Res 2023. | |||||
| 180 | sub study | Vlake JH, Van Bommel J, Wils EJ, et al. Effect of intensive care unit-specific virtual reality (ICU-VR) to improve psychological well-being and quality of life in COVID-19 ICU survivors: a study protocol for a multicentre, randomized controlled trial. Trials 2021; 22(1): 328. | |||||
| 270 | sub study | Voci D, Gotschi A, Held U, et al. Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial. Thromb Res 2023; 221: 157–63. | |||||
| 274 | sub study | Vollmuth C, Miljukov O, Abu-Mugheisib M, et al. Impact of the coronavirus disease 2019 pandemic on stroke teleconsultations in Germany in the first half of 2020. Eur J Neurol 2021; 28(10): 3267–78. | |||||
| 194 | under 30 in arm | Vuorio A, Brinck J, Kovanen PT. Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing. Ann Med 2022; 54(1): 1952–5. | |||||
| 207 | under 30 in arm | Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence. Cochrane Database Syst Rev 2022; 11(11): CD014963. | |||||
| 8 | duplicate citation | Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med 2021; 384(3): 238–51. | |||||
| 147 | duplicate citation | Xiang HR, He B, Li Y, Cheng X, Zhang QZ, Peng WX. Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis. J Med Virol 2022; 94(5): 1893–905. | |||||
| 154 | duplicate citation | Xu C, Yi T, Tan S, et al. Association of Oral or Intravenous Vitamin C Supplementation with Mortality: A Systematic Review and Meta-Analysis. Nutrients 2023; 15(8). | |||||
| 167 | duplicate citation | Yasein N, Shroukh W, Barghouti F, et al. The potential counter effect of COVID-19 outbreak on an antimicrobial agents prescribing educational intervention. J Infect Dev Ctries 2021; 15(11): 1653–60. | |||||
| 172 | duplicate citation | Yin W, Liu Y, Hu H, Sun J, Liu Y, Wang Z. Telemedicine management of type 2 diabetes mellitus in obese and overweight young and middle-aged patients during COVID-19 outbreak: A single-center, prospective, randomized control study. PLoS One 2022; 17(9): e0275251. | |||||
| 188 | duplicate citation | Zarabanda D, Vukkadala N, Phillips KM, et al. The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial. Laryngoscope 2022; 132(11): 2089–95. |